USD 0.49
(-13.84%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - USD | -100.0% |
2022 | 2.95 Million USD | -66.21% |
2021 | 8.75 Million USD | -44.39% |
2020 | 15.74 Million USD | -85.97% |
2019 | 112.2 Million USD | 16.07% |
2018 | 96.66 Million USD | 2.45% |
2017 | 94.35 Million USD | 3.84% |
2016 | 90.86 Million USD | 13.75% |
2015 | 79.87 Million USD | 343.38% |
2014 | 18.01 Million USD | 25.42% |
2013 | 14.36 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 6.52 Million USD | 3.37% |
2024 Q1 | 6.31 Million USD | 0.0% |
2023 FY | - USD | -100.0% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q1 | - USD | -100.0% |
2023 Q2 | - USD | 0.0% |
2022 Q2 | 3.35 Million USD | -96.17% |
2022 Q4 | 2.95 Million USD | -8.33% |
2022 FY | 2.95 Million USD | -66.21% |
2022 Q1 | 87.65 Million USD | -2.92% |
2022 Q3 | 3.22 Million USD | -3.9% |
2021 Q3 | 92.93 Million USD | -3.34% |
2021 Q4 | 90.29 Million USD | -2.84% |
2021 Q2 | 96.14 Million USD | -2.82% |
2021 Q1 | 98.93 Million USD | -4.97% |
2021 FY | 8.75 Million USD | -44.39% |
2020 Q4 | 104.11 Million USD | -2.62% |
2020 FY | 15.74 Million USD | -85.97% |
2020 Q1 | 113.34 Million USD | -2.15% |
2020 Q3 | 106.91 Million USD | -3.21% |
2020 Q2 | 110.45 Million USD | -2.55% |
2019 Q3 | 118.34 Million USD | -2.64% |
2019 Q2 | 121.54 Million USD | 22.56% |
2019 Q1 | 99.17 Million USD | 2.59% |
2019 FY | 112.2 Million USD | 16.07% |
2019 Q4 | 115.84 Million USD | -2.11% |
2018 Q4 | 96.66 Million USD | -0.6% |
2018 FY | 96.66 Million USD | 2.45% |
2018 Q3 | 97.24 Million USD | 0.84% |
2018 Q2 | 96.43 Million USD | 1.11% |
2018 Q1 | 95.37 Million USD | 1.08% |
2017 Q1 | 91 Million USD | 0.16% |
2017 Q3 | 93.51 Million USD | 1.29% |
2017 Q4 | 94.35 Million USD | 0.9% |
2017 Q2 | 92.32 Million USD | 1.45% |
2017 FY | 94.35 Million USD | 3.84% |
2016 Q2 | 75.18 Million USD | -3.04% |
2016 Q4 | 90.86 Million USD | 10.56% |
2016 Q3 | 82.17 Million USD | 9.31% |
2016 FY | 90.86 Million USD | 13.75% |
2016 Q1 | 77.53 Million USD | -2.93% |
2015 Q4 | 79.87 Million USD | -2.74% |
2015 Q2 | 13.62 Million USD | -14.05% |
2015 FY | 79.87 Million USD | 343.38% |
2015 Q3 | 82.12 Million USD | 502.83% |
2015 Q1 | 15.85 Million USD | -12.02% |
2014 FY | 18.01 Million USD | 25.42% |
2014 Q4 | 18.01 Million USD | -11.51% |
2014 Q1 | 14.49 Million USD | 0.89% |
2014 Q2 | 22.42 Million USD | 54.77% |
2014 Q3 | 20.35 Million USD | -9.23% |
2013 Q3 | 2.38 Million USD | -46.94% |
2013 Q1 | 6.54 Million USD | 0.0% |
2013 FY | 14.36 Million USD | 0.0% |
2013 Q4 | 14.36 Million USD | 502.26% |
2013 Q2 | 4.49 Million USD | -31.29% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 309.66 Million USD | 100.0% |
Aquestive Therapeutics, Inc. | 91.07 Million USD | 100.0% |
Collegium Pharmaceutical, Inc. | 489.96 Million USD | 100.0% |
Cosmos Health Inc. | 3.03 Million USD | 100.0% |
Dynavax Technologies Corporation | 252.41 Million USD | 100.0% |
Intra-Cellular Therapies, Inc. | 13.32 Million USD | 100.0% |
Pacira BioSciences, Inc. | 513.79 Million USD | 100.0% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 100.0% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 100.0% |
SCYNEXIS, Inc. | 12.15 Million USD | 100.0% |
Safety Shot Inc | 304.9 Thousand USD | 100.0% |
China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | 100.0% |
Alpha Teknova, Inc. | 13.25 Million USD | 100.0% |
Bright Green Corporation | 201.78 Thousand USD | 100.0% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 100.0% |
Embecta Corp. | 1.62 Billion USD | 100.0% |
PainReform Ltd. | 30 Thousand USD | 100.0% |
Journey Medical Corporation | 14.62 Million USD | 100.0% |
Procaps Group, S.A. | 28.41 Million USD | 100.0% |
Theratechnologies Inc. | 51.26 Million USD | 100.0% |
Harrow Health, Inc. | 183.17 Million USD | 100.0% |
Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | 100.0% |
Biofrontera Inc. | 804 Thousand USD | 100.0% |
DURECT Corporation | 2.7 Million USD | 100.0% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 100.0% |
Cronos Group Inc. | 1.55 Million USD | 100.0% |
OptiNose, Inc. | 611 Thousand USD | 100.0% |
Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 100.0% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | 100.0% |
RedHill Biopharma Ltd. | 455 Thousand USD | 100.0% |
Organogenesis Holdings Inc. | 60.74 Million USD | 100.0% |
Guardion Health Sciences, Inc. | - USD | NaN% |
Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 100.0% |
Radius Health, Inc. | 339.66 Million USD | 100.0% |
Universe Pharmaceuticals INC | - USD | NaN% |
ProPhase Labs, Inc. | 10.25 Million USD | 100.0% |
Phibro Animal Health Corporation | 458.28 Million USD | 100.0% |
Procaps Group S.A. | 28.41 Million USD | 100.0% |
Alvotech | 1.02 Billion USD | 100.0% |
TherapeuticsMD, Inc. | 6.53 Million USD | 100.0% |
Viatris Inc. | 16.18 Billion USD | 100.0% |
Rockwell Medical, Inc. | 8.29 Million USD | 100.0% |
Aytu BioPharma, Inc. | 10.87 Million USD | 100.0% |
SIGA Technologies, Inc. | 335.99 Thousand USD | 100.0% |
Tilray Brands, Inc. | 287.93 Million USD | 100.0% |
Lifecore Biomedical, Inc. | 120.51 Million USD | 100.0% |
Shineco, Inc. | 10.01 Million USD | 100.0% |
PetIQ, Inc. | 437.82 Million USD | 100.0% |
Regencell Bioscience Holdings Limited | - USD | NaN% |
Incannex Healthcare Limited | 210 Thousand USD | 100.0% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 100.0% |
Alimera Sciences, Inc. | 64.48 Million USD | 100.0% |
Silver Spike Investment Corp. | - USD | NaN% |
Assertio Holdings, Inc. | 38.51 Million USD | 100.0% |
Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | 100.0% |
Petros Pharmaceuticals, Inc. | 6.85 Million USD | 100.0% |
Clever Leaves Holdings Inc. | 720 Thousand USD | 100.0% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | 100.0% |
Avadel Pharmaceuticals plc | 32.75 Million USD | 100.0% |
Hempacco Co., Inc. | 5.93 Million USD | 100.0% |
Alvotech | 1.02 Billion USD | 100.0% |
Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 100.0% |
Lantheus Holdings, Inc. | 616.12 Million USD | 100.0% |
Currenc Group, Inc. | 2.5 Million USD | 100.0% |
Kamada Ltd. | 7.43 Million USD | 100.0% |
Indivior PLC | 235.66 Million USD | 100.0% |
Evoke Pharma, Inc. | 5 Million USD | 100.0% |
Flora Growth Corp. | 942 Thousand USD | 100.0% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | 100.0% |
Evolus, Inc. | 120.35 Million USD | 100.0% |
HUTCHMED (China) Limited | 48.18 Million USD | 100.0% |
Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 100.0% |
Akanda Corp. | 2.49 Million USD | 100.0% |